OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Lærke S. Gasbjerg, Mads M. Helsted, Bolette Hartmann, et al.
Diabetes (2019) Vol. 68, Iss. 5, pp. 906-917
Open Access | Times Cited: 155
Lærke S. Gasbjerg, Mads M. Helsted, Bolette Hartmann, et al.
Diabetes (2019) Vol. 68, Iss. 5, pp. 906-917
Open Access | Times Cited: 155
Showing 1-25 of 155 citing articles:
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 664
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 664
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 361
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 361
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
The carbohydrate-insulin model: a physiological perspective on the obesity pandemic
David S. Ludwig, Louis J. Aronne, Arne Astrup, et al.
American Journal of Clinical Nutrition (2021) Vol. 114, Iss. 6, pp. 1873-1885
Open Access | Times Cited: 223
David S. Ludwig, Louis J. Aronne, Arne Astrup, et al.
American Journal of Clinical Nutrition (2021) Vol. 114, Iss. 6, pp. 1873-1885
Open Access | Times Cited: 223
The evolving story of incretins (GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min, Stephen C. Bain
Diabetes Therapy (2020) Vol. 12, Iss. 1, pp. 143-157
Open Access | Times Cited: 207
Thinzar Min, Stephen C. Bain
Diabetes Therapy (2020) Vol. 12, Iss. 1, pp. 143-157
Open Access | Times Cited: 207
The incretin system in healthy humans: The role of GIP and GLP-1
Jens J. Holst
Metabolism (2019) Vol. 96, pp. 46-55
Open Access | Times Cited: 183
Jens J. Holst
Metabolism (2019) Vol. 96, pp. 46-55
Open Access | Times Cited: 183
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 183
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 183
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla Collins, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 150
Ricardo J. Samms, Michael E. Christe, Kyla Collins, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 150
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Daniel B. Maselli, Michael Camilleri
Advances in experimental medicine and biology (2020), pp. 171-192
Closed Access | Times Cited: 144
Daniel B. Maselli, Michael Camilleri
Advances in experimental medicine and biology (2020), pp. 171-192
Closed Access | Times Cited: 144
Metabolic Messengers: glucagon-like peptide 1
Fiona M. Gribble, Frank Reimann
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 142-148
Closed Access | Times Cited: 143
Fiona M. Gribble, Frank Reimann
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 142-148
Closed Access | Times Cited: 143
The metabolic impact of small intestinal nutrient sensing
Frank A. Duca, T.M. Zaved Waise, Willem T. Peppler, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 128
Frank A. Duca, T.M. Zaved Waise, Willem T. Peppler, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 128
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 128
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 128
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 118
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 118
Whole grain benefit: synergistic effect of oat phenolic compounds and β-glucan on hyperlipidemiaviagut microbiota in high-fat-diet mice
Ying Li, Chuan Qin, Lezhen Dong, et al.
Food & Function (2022) Vol. 13, Iss. 24, pp. 12686-12696
Closed Access | Times Cited: 84
Ying Li, Chuan Qin, Lezhen Dong, et al.
Food & Function (2022) Vol. 13, Iss. 24, pp. 12686-12696
Closed Access | Times Cited: 84
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 82
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 82
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 80
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 80
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block, Clifford J. Bailey, Carol Wysham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 3-17
Open Access | Times Cited: 71
Christophe De Block, Clifford J. Bailey, Carol Wysham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 3-17
Open Access | Times Cited: 71
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 57
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 57
Adverse Events Related to Tirzepatide
Rahul Mishra, Rishi Raj, Ghada Elshimy, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 51
Rahul Mishra, Rishi Raj, Ghada Elshimy, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 51
Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Ajit Regmi, Eitaro Aihara, Michael E. Christe, et al.
Cell Metabolism (2024) Vol. 36, Iss. 7, pp. 1534-1549.e7
Open Access | Times Cited: 27
Ajit Regmi, Eitaro Aihara, Michael E. Christe, et al.
Cell Metabolism (2024) Vol. 36, Iss. 7, pp. 1534-1549.e7
Open Access | Times Cited: 27
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 21
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 21
The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreaticβ-Cell Function and Diabetes
Matthew J. Varney, Jeffrey Benovic
Pharmacological Reviews (2024) Vol. 76, Iss. 2, pp. 267-299
Open Access | Times Cited: 18
Matthew J. Varney, Jeffrey Benovic
Pharmacological Reviews (2024) Vol. 76, Iss. 2, pp. 267-299
Open Access | Times Cited: 18
